OKYO Pharma Limited Issue of Equity (6062Q)
01 March 2021 - 6:00PM
UK Regulatory
TIDMOKYO
RNS Number : 6062Q
OKYO Pharma Limited
01 March 2021
ISSUE OF EQUITY
1 March 2021
OKYO Pharma Limited ("OKYO" or the "Company") today announces
that it has issued 250,000 ordinary shares of no par value
("Ordinary Shares"), credited as fully paid, at a price of 4.5p per
share on the exercise of 250,000 options.
Applications will be made to the FCA and to the London Stock
Exchange for Admission in respect of all the 250,000 Ordinary
Shares. It is expected that Admission will become effective, and
that dealings in the new Ordinary Shares are expected to commence,
at 8.00 a.m. on 3 March 2021.
Following Admission of the new Ordinary Shares, the enlarged
Share Capital will be 672,816,302 ordinary shares of no par
value.
The person who arranged for the release of this announcement on
behalf of the Company was Keeren Shah, Chief Financial Officer of
OKYO.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF UK MARKET ABUSE REGULATION.
About OKYO
OKYO Pharma Limited (LSE: OKYO) is a life sciences and
biotechnology company admitted to listing on the standard segment
of the Official List of the UK Financial Conduct Authority and to
trading on the Main Market for listed securities of the London
Stock Exchange plc. OKYO is focusing on the discovery and
development of novel molecules to treat inflammatory dry eye
diseases and ocular pain.
Enquiries:
OKYO Pharma Limited Willy Simon +44 (0)20 7495 2379
Optiva Securities Limited Robert Emmet +44 (0)20 3981 4173
For further information, please visit the Company's website at
www.okyopharma.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFFFVLFAITFIL
(END) Dow Jones Newswires
March 01, 2021 02:00 ET (07:00 GMT)
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From Apr 2024 to May 2024
Okyo Pharma (LSE:OKYO)
Historical Stock Chart
From May 2023 to May 2024